Humans; Pregnancy; Female; Placenta Accreta/therapy; Placenta Accreta/diagnosis; Practice Guidelines as Topic; Placenta Accreta; Medicine (all)
Abstract :
[en] [en] IMPORTANCE: Placenta accreta spectrum (PAS) is a complex, life-threatening condition that demands a multidisciplinary approach involving obstetrics, maternal-fetal medicine, and various surgical and medical specialties. Effective management relies on multispecialty collaboration and consensus, supported by standardized protocols, to optimize outcomes, guide informed clinical decisions, and mitigate the risks associated with PAS.
OBJECTIVE: To examine clinical practice guidelines for PAS inclusive of high-income countries and low- to middle-income countries (LMICs) identifying areas of consensus and gaps in guidance.
EVIDENCE REVIEW: A comprehensive search of PubMed, GIN Library, and ECRI Guidelines Trust identified all PAS-related clinical practice guidelines published from January 1, 2014, to January 31, 2024. Additional searches included professional societies' designated websites and cited references. Two independent reviewers screened the guidelines, resolving conflicts through cross-referencing. Initially, 2 independent reviewers provided structured review and feedback to refine, correct, or highlight areas of consensus, disagreement, or insufficient evidence. Any instances of nonagreement were adjudicated by majority panel agreement, arising from a panel of 15 to 18 experts, all authors of PAS guidelines. Agreement scores for each recommendation area (eg, epidemiology, diagnosis, and antenatal management) were categorized as high agreement (≥75%), poor consensus (<50% or ≥30% insufficient evidence), and high levels of insufficient evidence (≥50% of recommendations with insufficient evidence) based on a priori score criteria.
FINDINGS: A total of 14 guidelines from 18 articles from national and international societies were included. High agreement was noted in areas such as specialized expertise (100%), antenatal management (88.9%), diagnosis (76.9%), and epidemiology (75.0%). Poor consensus characterized cesarean hysterectomy management (38.5% insufficient evidence and 23.0% disagreement), conservative techniques (33.3% insufficient evidence and 11.1% disagreement), and fertility counseling (30.0% insufficient evidence and 10.0% disagreement). Despite the high risk of anemia, consensus was lacking on iron supplementation strategies. Recommendations for thromboembolism prevention varied, with some guidelines favoring pharmacologic interventions and others advocating for nonpharmacologic measures. Hemorrhage management and postnatal management recommendations, including iron supplementation and thromboembolism prevention, were characterized by high levels of insufficient evidence (55.6% and 57.1%, respectively). Only 1 article (5.6%) specifically addressed LMICs, highlighting substantial underrepresentation.
CONCLUSIONS AND RELEVANCE: This systematic review of PAS guidelines identified significant discrepancies and insufficient evidence in key aspects of care. The findings underscore the urgent need for further research and quality measures to enhance standardized approaches and improve patient outcomes. The limited availability of recommendations applicable to LMICs highlights the critical need for tailored guidance that accounts for resource constraints and clinical access challenges unique to these settings.
Disciplines :
Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Bonanni, Giulia; Fetal Care and Surgery Center, Division of Fetal Medicine and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts ; Department of Women, Children, and Public Health Sciences, IRCCS Agostino Gemelli University Polyclinic Foundation, Catholic University of the Sacred Heart, Rome, Italy
Lopez-Giron, Maria C; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia
Allen, Lisa; Section of Pediatric and Adolescent Gynecology, The Hospital for Sick Children, Department of Obstetrics and Gynecology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada ; Department of Obstetrics and Gynecology, Mount Sinai Hospital, Toronto, Ontario, Canada
Fox, Karin; Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston
Silver, Robert M; Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City
Hobson, Sebastian R; Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
Nieto-Calvache, Albaro J; Clinica de Espectro de Acretismo Placentario, Fundacion Valle de Lili, Cali, Colombia
Collins, Sally; Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK ; Fetal Medicine Unit, John Radcliffe Hospital, Oxford, UK
Wielgos, Miroslaw; Department of Obstetrics and Perinatology, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland
Jauniaux, Eric; EGA Institute for Women's Health, Faculty of Population Health Sciences, University College London, London, UK
Bartels, Helena C; Department of Obstetrics and Gynaecology, National Maternity Hospital, University College Dublin School of Medicine, Dublin, Ireland
Sentilhes, Loïc; Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France
Kingdom, John; Department of Obstetrics and Gynecology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
Chantraine, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique (CHR)
Wax, Joseph R; Division of Maternal-Fetal Medicine, Maine Medical Center, Portland
Cahill, Alison; Department of Women's Health, University of Texas at Austin, Dell Medical School, Austin
Abuhamad, Alfred; Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk
de-Campos, Diogo Ayres; Lisbon Medical School, University of Lisbon, Santa Maria University Hospital, Lisbon, Portugal
Aagaard, Kjersti; Fetal Care and Surgery Center, Division of Fetal Medicine and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts ; HCA Healthcare Research Institute, HCA Healthcare, Nashville, Tennessee ; Texas Maternal Fetal Medicine, HCA Healthcare, Houston
Shamshirsaz, Amir A; Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas
Shainker, Scott A; Fetal Care and Surgery Center, Division of Fetal Medicine and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts ; Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts ; Department of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, Massachusetts
Shamshirsaz, Alireza A; Fetal Care and Surgery Center, Division of Fetal Medicine and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts
Conflict of Interest Disclosures: Dr Fox reported receiving grants from Koch Foundation, serving on the editorial board for Elsevier Inc, writing for Wolters-Kluwer UpToDate, receiving travel expenses from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, other from Pan-American Society for the Place at Accreta Spectrum Treasurer, and serving as a board member for International Society for Placenta Accreta Spectrum outside the submitted work. Dr Sentilhes reported receiving personal fees, performing consultancy work, and lecturing for Ferring Pharmaceuticals, Bayer, Pfizer, and Organon and lecturing for Norgine outside the submitted work. Dr Wax reported receiving royalties from UptoDate outside the submitted work. Dr Shainker reported receiving grants from Chase Koch Foundation and royalties from Oxford University Press outside the submitted work. No other disclosures were reported.
Shamshirsaz AA, Fox KA, Salmanian B, et al. Maternal morbidity in patients with morbidly adherent placenta treated with and without a standardized multidisciplinary approach. Am J Obstet Gynecol. 2015;212(2):218.e1-218.e9. doi:10.1016/j.ajog.2014.08.019
Jauniaux E, Bunce C, Grønbeck L, Langhoff-Roos J. Prevalence and main outcomes of placenta accreta spectrum: a systematic review and meta-analysis. Am J Obstet Gynecol. 2019;221(3):208-218. doi:10.1016/j.ajog.2019.01.233
Fonseca A, Ayres de Campos D. Maternal morbidity and mortality due to placenta accreta spectrum disorders. Best Pract Res Clin Obstet Gynaecol. 2021;72:84-91. doi:10.1016/j.bpobgyn.2020.07.011
Capannolo G, D’Amico A, Alameddine S, et al. Placenta accreta spectrum disorders clinical practice guidelines: a systematic review. J Obstet Gynaecol Res. 2023;49(5):1313-1321. doi:10.1111/jog.15544
Jauniaux E, Kingdom JC, Silver RM. A comparison of recent guidelines in the diagnosis and management of placenta accreta spectrum disorders. Best Pract Res Clin Obstet Gynaecol. 2021;72:102-116. doi:10.1016/j.bpobgyn.2020.06.007
Giouleka S, Tsakiridis I, Chanioti ER, et al. Placenta accreta spectrum: a comprehensive review of guidelines. Obstet Gynecol Surv. 2024;79(6):366-381. doi:10.1097/OGX.0000000000001274
Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020;368:l6890. doi:10.1136/bmj.l6890
Azarpira M, Redjdal A, Bouaud J, Seroussi B. Methods used to compare narrative clinical practice guidelines: a scoping review. Stud Health Technol Inform. 2022;295:304-307. doi:10.3233/SHTI220723
Gu Z. Complex heatmap visualization. iMeta. 2022;1(3):e43.
Allen L, Jauniaux E, Hobson S, Papillon-Smith J, Belfort MA; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: nonconservative surgical management. Int J Gynaecol Obstet. 2018;140(3):281-290. doi:10.1002/ijgo.12409
Bartels HC, Walsh JM, Ní Mhuircheartaigh R, et al. National Clinical Practice Guideline: Diagnosis and management of placenta accreta spectrum. National Women and Infants Health Programme and Institute of Obstetricians and Gynaecologists. December 2022. Accessed June 18, 2025. https://www.hse.ie/eng/about/who/acute-hospitals-division/woman-infants/clinical-guidelines/diagnosis-and-management-of-placentaaccreta-spectrum.pdf
Cahill AG, Beigi R, Heine RP, Silver RM, Wax JR; Society of Gynecologic Oncology; American College of Obstetricians and Gynecologists and the Society for Maternal–Fetal Medicine. Placenta accreta spectrum. Am J Obstet Gynecol. 2018;219(6):B2-B16. doi:10.1016/j.ajog.2018.09.042
Collins SL, Alemdar B, van Beekhuizen HJ, et al; International Society for Abnormally Invasive Placenta (IS-AIP). Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta. Am J Obstet Gynecol. 2019;220(6):511-526. doi:10.1016/j.ajog.2019.02.054
Hobson SR, Kingdom JC, Murji A, et al. No. 383-screening, diagnosis, and management of placenta accreta spectrum disorders. J Obstet Gynaecol Can. 2019;41(7):1035-1049. doi:10.1016/j.jogc.2018.12.004
Jauniaux E, Alfirevic Z, Bhide AG, et al; Royal College of Obstetricians and Gynaecologists. Placenta praevia and placenta accreta: diagnosis and management: Green-top Guideline No. 27a. BJOG. 2019;126(1):e1-e48. doi:10.1111/1471-0528.15306
Jauniaux E, Ayres-de-Campos D; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: introduction. Int J Gynaecol Obstet. 2018;140 (3):261-264. doi:10.1002/ijgo.12406
Jauniaux E, Bhide A, Kennedy A, Woodward P, Hubinont C, Collins S; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: prenatal diagnosis and screening. Int J Gynaecol Obstet. 2018;140(3):274-280. doi:10.1002/ijgo.12408
Jauniaux E, Chantraine F, Silver RM, Langhoff-Roos J; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Epidemiology. Int J Gynaecol Obstet. 2018;140(3):265-273. doi:10.1002/ijgo.12407
Nieto-Calvache AJ, Sanín-Blair JE, Buitrago-Leal HM, et al. Colombian Consensus on the Treatment of Placenta Accreta Spectrum (PAS). Rev Colomb Obstet Ginecol. 2022;73(3):283-316. doi:10.18597/rcog.3877
RANZCOG Women’s Health Committee. Placenta Accreta Spectrum (PAS) (C-Obs 20). Accessed August 30, 2024. https://ranzcog.edu.au/wp-content/uploads/Placenta-Accreta-Spectrum.pdf
Anomalías de la inserción placentaria y vasos sanguíneos fetales. Guía de Práctica Clínica. Primera edicion. Accessed August 28, 2024. https://www.salud.gob.ec/wp-content/uploads/2014/05/GPC-ANOMALIASINSERCION-PLACENTARIA-17-01-2017.pdf
Sentilhes L, Kayem G, Chandraharan E, Palacios-Jaraquemada J, Jauniaux E; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: conservative management. Int J Gynaecol Obstet. 2018;140(3):291-298. doi:10.1002/ijgo.12410
Shainker SA, Coleman B, Timor-Tritsch IE, et al; Society for Maternal-Fetal Medicine. Special Report of the Society for Maternal-Fetal Medicine Placenta Accreta Spectrum Ultrasound Marker Task Force: consensus on definition of markers and approach to the ultrasound examination in pregnancies at risk for placenta accreta spectrum. Am J Obstet Gynecol. 2021;224(1):B2-B14. doi:10.1016/j.ajog.2020.09.001
Annecke T, Lier H, Girard T, et al. Peripartale Blutungen, Diagnostik und Therapie: Update der S2k-Leitlinie AWMF 015/063 vom August 2022. [Peripartum hemorrhage, diagnostics and treatment: Update of the S2k guidelines AWMF 015/063 from August 2022]. Anaesthesiologie. 2022;71(12):952-958. doi:10.1007/s00101-022-01224-6
Sentilhes L, Vayssière C, Deneux-Tharaux C, et al. Postpartum hemorrhage: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF): in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR). Eur J Obstet Gynecol Reprod Biol. 2016;198:12-21. doi:10.1016/j.ejogrb.2015.12.012
Wielgos M, Bomba-Opoń D, Breborowicz GH, et al. Recommendations of the Polish Society of Gynecologists and Obstetricians regarding caesarean sections. Ginekol Pol. 2018;89(11):644-657. doi:10.5603/GP.a2018.0110
Silver RM, Landon MB, Rouse DJ, et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol. 2006;107(6):1226-1232. doi:10.1097/01.AOG.0000219750.79480.84
Klar M, Michels KB. Cesarean section and placental disorders in subsequent pregnancies–a meta-analysis. J Perinat Med. 2014;42(5):571-583. doi:10.1515/jpm-2013-0199
Thurn L, Lindqvist PG, Jakobsson M, et al. Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries. BJOG. 2016;123 (8):1348-1355. doi:10.1111/1471-0528.13547
D’Antonio F, Iacovella C, Bhide A. Prenatal identification of invasive placentation using ultrasound: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2013;42(5):509-517. doi:10.1002/uog.13194
Jauniaux E, Collins SL, Jurkovic D, Burton GJ. Accreta placentation: a systematic review of prenatal ultrasound imaging and grading of villous invasiveness. Am J Obstet Gynecol. 2016;215(6):712-721. doi:10.1016/j.ajog.2016.07.044
Ker K, Sentilhes L, Shakur-Still H, et al; Anti-fibrinolytics Trialists Collaborators Obstetric Group. Tranexamic acid for postpartum bleeding: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet. 2024;404(10463):1657-1667. doi:10.1016/S0140-6736(24)02102-0
WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105-2116. doi:10.1016/S0140-6736(17)30638-4
Bartels HC, Walsh JM, O’Connor C, et al. Placenta accreta spectrum ultrasound stage and fetal growth. Int J Gynaecol Obstet. 2023;160(3):955-961. doi:10.1002/ijgo.14399
Jauniaux E, Dimitrova I, Kenyon N, et al. Impact of placenta previa with placenta accreta spectrum disorder on fetal growth. Ultrasound Obstet Gynecol. 2019;54(5):643-649. doi:10.1002/uog.20244
Bartels HC, Horsch A, Cooney N, Brennan DJ, Lalor JG. Living with a diagnosis of placenta accreta spectrum: mothers’ and fathers’ experience of the antenatal journey and the birth. PLoS One. 2023;18(5):e0286082. doi:10.1371/journal.pone.0286082
Bartels HC, Horsch A, Cooney N, Brennan DJ, Lalor JG. Living beyond placenta accreta spectrum: parent’s experience of the postnatal journey and recommendations for an integrated care pathway. BMC Pregnancy Childbirth. 2022;22(1):397. doi:10.1186/s12884-022-04726-8
Einerson BD, Watt MH, Sartori B, Silver R, Rothwell E. Lived experiences of patients with placenta accreta spectrum in Utah: a qualitative study of semi-structured interviews. BMJ Open. 2021;11(11):e052766. doi:10.1136/bmjopen-2021-052766
Nieto-Calvache AJ, Jauniaux E, Fox KA, et al; International Society for PAS (IS-PAS) LMIC Working Group. Are international guideline recommendations for the management of placenta accreta spectrum applicable in low- and middle-income countries? Int J Gynaecol Obstet. 2024;166(3):1047-1056. doi:10.1002/ijgo.15473
Based on the medium fertility variant of the United Nation Revision of World Population Prospects 2022. Accessed July 13, 2024. https://database.earth/population/births/2023
Betran AP, Ye J, Moller AB, Souza JP, Zhang J. Trends and projections of caesarean section rates: global and regional estimates. BMJ Glob Health. 2021;6(6):e005671. doi:10.1136/bmjgh-2021-005671